Gavin Malenfant
Chief Operating Officer at ProMIS™ Neurosciences, Inc.- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
Topline Score
Bio
Bruce M Wentworth
Gavin is one of the best executive level Operations and Program Management leaders I've worked with in my biotech career. He rapidly brought clarity to forward-thinking decision making in the complex process of antisense drug manufacturing, and also helped me to integrate R&D activity into a portfolio-based, rationally designed system. Furthermore, he is a superb mentor, connecting and identifying the professional needs of colleagues at all levels of an organization, an essential quality for leaders in young organizations.
Timothy M Miller
Gavin is one of the most professional and trustworthy leaders I have worked with in the pharamcuetical industry. He has impecably high standards, is detailed oriented and yet able to see the big picture when it comes to specific project or development area pull through. Throughout my time working alongside him at Genzyme, he has been a truly impactful leader of individuals and of cross functional teams. He is a leader that people flock to when the desired outcome is success and one that is both inspirational and kind. He sees successfully leading people as part of his mandate as a professional executive and has an impressive list of partners who continue to see the results of his diligent and precise work daily. Gavin is highly knowledgeable in the key aspects of bringing novel therapuetic programs from the idea phase through to approval and continuously seeks to increase his own skills and those of the teams he leads. Finally, Gavin is a pleasure to work and succeed alongside. I cannot imagine a company or endeavor, for that matter, which I would not feel more confident about its success with his involvement.
Bruce M Wentworth
Gavin is one of the best executive level Operations and Program Management leaders I've worked with in my biotech career. He rapidly brought clarity to forward-thinking decision making in the complex process of antisense drug manufacturing, and also helped me to integrate R&D activity into a portfolio-based, rationally designed system. Furthermore, he is a superb mentor, connecting and identifying the professional needs of colleagues at all levels of an organization, an essential quality for leaders in young organizations.
Timothy M Miller
Gavin is one of the most professional and trustworthy leaders I have worked with in the pharamcuetical industry. He has impecably high standards, is detailed oriented and yet able to see the big picture when it comes to specific project or development area pull through. Throughout my time working alongside him at Genzyme, he has been a truly impactful leader of individuals and of cross functional teams. He is a leader that people flock to when the desired outcome is success and one that is both inspirational and kind. He sees successfully leading people as part of his mandate as a professional executive and has an impressive list of partners who continue to see the results of his diligent and precise work daily. Gavin is highly knowledgeable in the key aspects of bringing novel therapuetic programs from the idea phase through to approval and continuously seeks to increase his own skills and those of the teams he leads. Finally, Gavin is a pleasure to work and succeed alongside. I cannot imagine a company or endeavor, for that matter, which I would not feel more confident about its success with his involvement.
Bruce M Wentworth
Gavin is one of the best executive level Operations and Program Management leaders I've worked with in my biotech career. He rapidly brought clarity to forward-thinking decision making in the complex process of antisense drug manufacturing, and also helped me to integrate R&D activity into a portfolio-based, rationally designed system. Furthermore, he is a superb mentor, connecting and identifying the professional needs of colleagues at all levels of an organization, an essential quality for leaders in young organizations.
Timothy M Miller
Gavin is one of the most professional and trustworthy leaders I have worked with in the pharamcuetical industry. He has impecably high standards, is detailed oriented and yet able to see the big picture when it comes to specific project or development area pull through. Throughout my time working alongside him at Genzyme, he has been a truly impactful leader of individuals and of cross functional teams. He is a leader that people flock to when the desired outcome is success and one that is both inspirational and kind. He sees successfully leading people as part of his mandate as a professional executive and has an impressive list of partners who continue to see the results of his diligent and precise work daily. Gavin is highly knowledgeable in the key aspects of bringing novel therapuetic programs from the idea phase through to approval and continuously seeks to increase his own skills and those of the teams he leads. Finally, Gavin is a pleasure to work and succeed alongside. I cannot imagine a company or endeavor, for that matter, which I would not feel more confident about its success with his involvement.
Bruce M Wentworth
Gavin is one of the best executive level Operations and Program Management leaders I've worked with in my biotech career. He rapidly brought clarity to forward-thinking decision making in the complex process of antisense drug manufacturing, and also helped me to integrate R&D activity into a portfolio-based, rationally designed system. Furthermore, he is a superb mentor, connecting and identifying the professional needs of colleagues at all levels of an organization, an essential quality for leaders in young organizations.
Timothy M Miller
Gavin is one of the most professional and trustworthy leaders I have worked with in the pharamcuetical industry. He has impecably high standards, is detailed oriented and yet able to see the big picture when it comes to specific project or development area pull through. Throughout my time working alongside him at Genzyme, he has been a truly impactful leader of individuals and of cross functional teams. He is a leader that people flock to when the desired outcome is success and one that is both inspirational and kind. He sees successfully leading people as part of his mandate as a professional executive and has an impressive list of partners who continue to see the results of his diligent and precise work daily. Gavin is highly knowledgeable in the key aspects of bringing novel therapuetic programs from the idea phase through to approval and continuously seeks to increase his own skills and those of the teams he leads. Finally, Gavin is a pleasure to work and succeed alongside. I cannot imagine a company or endeavor, for that matter, which I would not feel more confident about its success with his involvement.
Experience
-
ProMIS™ Neurosciences, Inc.
-
Canada
-
Biotechnology Research
-
1 - 100 Employee
-
Chief Operating Officer
-
Jan 2022 - Present
-
-
-
GMalenfant Consulting
-
Cambridge, Unitied States
-
Founder
-
May 2018 - Jan 2022
• Corporate Strategy, driving corporate strategic initiatives to reach corporate objectives. • Program and Portfolio Management, global therapeutic strategy development and execution. • Business Development, drive evaluation of external licensing and partnership opportunities and lead intake for buy side opportunities. • Corporate Strategy, driving corporate strategic initiatives to reach corporate objectives. • Program and Portfolio Management, global therapeutic strategy development and execution. • Business Development, drive evaluation of external licensing and partnership opportunities and lead intake for buy side opportunities.
-
-
-
M6P Therapeutics
-
United States
-
Biotechnology Research
-
1 - 100 Employee
-
Program Management Consultant
-
Jun 2020 - Dec 2021
Program Management leadership for developing a rare disease asset for the clinic. Management of portfolio prioritization. Management of CDMO's, CRO's, and SME Consultants. Program Management leadership for developing a rare disease asset for the clinic. Management of portfolio prioritization. Management of CDMO's, CRO's, and SME Consultants.
-
-
-
Verge Genomics
-
United States
-
Biotechnology Research
-
1 - 100 Employee
-
Program Management Consultant
-
Oct 2020 - Nov 2021
Program management for lead asset being developed for neurodegenerative market. Facilitative leadership in executing IND enabling studies by integrating Verge staff, SME consultants, CDMO's and CRO's. Program management for lead asset being developed for neurodegenerative market. Facilitative leadership in executing IND enabling studies by integrating Verge staff, SME consultants, CDMO's and CRO's.
-
-
-
PepGen
-
United States
-
Biotechnology
-
1 - 100 Employee
-
Program Management Consultant
-
Jan 2021 - Oct 2021
Program Management leadership for Series A company's lead asset for rare neuromuscular disease. Program Management leadership for Series A company's lead asset for rare neuromuscular disease.
-
-
-
Vanqua Bio
-
United States
-
Biotechnology
-
1 - 100 Employee
-
Program Manager Consultant
-
Jan 2021 - Jun 2021
Provided development planning and benchmarking inclusive of durations, costs and integration for assets aimed at the neurodegenerative therapeutic market. Provided development planning and benchmarking inclusive of durations, costs and integration for assets aimed at the neurodegenerative therapeutic market.
-
-
-
Yumanity Therapeutics
-
United States
-
Biotechnology Research
-
1 - 100 Employee
-
Program Management Consultant
-
Dec 2020 - Feb 2021
Provided interim program management for lead asset for neurodegenerative market and consultation on Program Management function within the company. Provided interim program management for lead asset for neurodegenerative market and consultation on Program Management function within the company.
-
-
-
Tiburio Therapeutics
-
Cambridge, Massachusetts, United States
-
Program Management Consultant
-
Jan 2019 - Dec 2020
Program Management and scenario planning for a Series A company with a Phase 2 ready asset aimed at the rare disease market. Program Management and scenario planning for a Series A company with a Phase 2 ready asset aimed at the rare disease market.
-
-
-
ProMIS™ Neurosciences, Inc.
-
Canada
-
Biotechnology Research
-
1 - 100 Employee
-
Program Management Consultant
-
May 2018 - Mar 2020
Program managed a preclinical asset towards the clinic by integrating ProMIS team members, CDMO's, CRO's and subject matter expert consultants. Program managed a preclinical asset towards the clinic by integrating ProMIS team members, CDMO's, CRO's and subject matter expert consultants.
-
-
-
Vor Bio
-
United States
-
Biotechnology Research
-
100 - 200 Employee
-
Program Management Consultant
-
Feb 2019 - Nov 2019
Provided program management leadership for lead asset during Series A start up. Asset used cell therapy modality targeting the oncology market. Provided program management leadership for lead asset during Series A start up. Asset used cell therapy modality targeting the oncology market.
-
-
-
Akouos
-
United States
-
Biotechnology
-
1 - 100 Employee
-
Program Management Consultant
-
Jun 2018 - Sep 2018
Provided program management leadership to lead asset for Akouos during Series A start up. Lead asset aimed at the neurology market. Provided program management leadership to lead asset for Akouos during Series A start up. Lead asset aimed at the neurology market.
-
-
-
Akebia Therapeutics
-
United States
-
Biotechnology Research
-
100 - 200 Employee
-
Head of Corporate Operations and Program Management
-
Sep 2016 - May 2018
Established strategic priorities, translated strategies into actionable and measurable plans. •Achieved corporate goals by implementing a quarterly business review process to align to and monitor progress to corporate objectives. •Drove portfolio decision making process to ensure capital resources were applied efficiently. Established strategic priorities, translated strategies into actionable and measurable plans. •Achieved corporate goals by implementing a quarterly business review process to align to and monitor progress to corporate objectives. •Drove portfolio decision making process to ensure capital resources were applied efficiently.
-
-
-
Sarepta Therapeutics
-
United States
-
Biotechnology Research
-
700 & Above Employee
-
Head of Operations
-
May 2015 - Sep 2016
Delivered on time performance of EXONDYS51TM submission by utilizing change management practices to transform a command and control organization to a cross-functional. Integrated Sarepta's Development, CMC and Commercial teams in preparation of EXONDYS51TM launch. Project managed the rapid build and integration of a commercial team in support of EXONDYS51TM. Delivered on time performance of EXONDYS51TM submission by utilizing change management practices to transform a command and control organization to a cross-functional. Integrated Sarepta's Development, CMC and Commercial teams in preparation of EXONDYS51TM launch. Project managed the rapid build and integration of a commercial team in support of EXONDYS51TM.
-
-
-
Sanofi
-
France
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Head of Operations Genzyme Research and Development Center
-
Jul 2013 - May 2015
Provided operational management of the Genzyme research and development arm of Sanofi made up of ~400 employees working on all stages of drug development, as well as the research and discovery aspect of the Rare Disease and Multiple Sclerosis therapeutic areas.•Ensured that the senior management team was aligned on the strategy and goals of the unit. Managed Genzyme's Portfolio Management Committee, assessing development projects for go/no-go decisions. •Generated and managed long range planning, budgeting and forecasting Show less
-
-
Vice President Program & Portfolio Management
-
Feb 2008 - Jul 2013
Led the R&D Portfolio for the Rare Disease business unit.•Executed the Rare Disease business unit strategy with the R&D functions resulting in a business with ~$4B of annual revenue growing ~12% per year. •Led the development of the following products: Myozyme for Pompe disease. Cerdelga, substrate reduction therapy for Gaucher disease. Aldurazyme for MPSI. •Generated long range plans, budgets and forecasts ensuring that investments were optimized for the development of transformative products in a sustainable manner.•Hired, developed and managed a group of program managers. Show less
-
-
-
-
Director / Senior Director Program Management
-
Feb 1996 - Feb 2008
SENIOR DIRECTOR PROGRAM MANAGEMENT (2005-2008) Responsible for the late stage development programs for the Lysosomal Storage Disorder franchise and the pre-clinical and clinical programs in support of portfolio expansion through four program managers. •Led the registration of Myozyme that today delivers annual revenues over $650M. •Supported portfolio expansion efforts by collaborating with gene therapy programs targeting Age Related Macular Degeneration, Parkinson's Disease and Hemophilia. DIRECTOR PROGRAM MANAGEMENT (2000-2005) •Managed a cross-functional global development team across 52 functions resulting in the approval of Myozyme® utilizing a novel short track approach. Myozyme delivers annual revenues of over $650M. •Program managed Aldurazyme,® a joint venture between Genzyme and BioMarin, which today delivers annual revenues of ~$400M. DIRECTOR, BUSINESS DEVELOPMENT (1999-2000) •In-licensed rights for MPS IV (Morquio) and established a multinational research program. •In-licensed rights for a small molecule approach for Lysosomal Storage Diseases. SENIOR PROJECT MANAGER (1996-1999) •Established a team that formulated a potent peptide into a 90-day release formulation for prostate cancer and gained regulatory approval for a liquid formulation. Show less
-
-
-
Repligen Corporation
-
United States
-
Biotechnology Research
-
700 & Above Employee
-
Manager
-
Mar 1987 - Feb 1996
MANUFACTURING MANAGER (1994-1996) SECTION HEAD (1992-1994) LEAD PRODUCTION SUPERVISOR (1990-1992) PRODUCTION SUPERVISOR (1987 -1990) MANUFACTURING TECHNICIAN (1986-1987) MANUFACTURING MANAGER (1994-1996) SECTION HEAD (1992-1994) LEAD PRODUCTION SUPERVISOR (1990-1992) PRODUCTION SUPERVISOR (1987 -1990) MANUFACTURING TECHNICIAN (1986-1987)
-
-
Education
-
1982 - 1986
UMass Boston
Bachelor of Science, Biology
Community
